Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methyldopate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.66 |
| ▸ | BLM | P54132 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | APEX1 | P27695 | 2/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | FYN | P06241 | 1/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyldopate SCHEMBL29587132 | 1.00 | HSD17B10 (0.66) | HSD17B10KDM4EPOLBMAPTHPGD | |
| Methyldopate SCHEMBL11430187 | 1.00 | HSD17B10 (0.66) | HSD17B10KDM4EPOLBMAPTHPGD | |
| Methyldopate SCHEMBL41131 | 0.99 | KDM4E (0.64) | HSD17B10KDM4EPOLBMAPTHPGD | |
| SCHEMBL24761068 | 0.90 | KDM4E (0.64) | HSD17B10KDM4EPOLBMAPTHPGD | |
| SCHEMBL29881538 | 0.90 | KDM4E (0.64) | HSD17B10KDM4EPOLBMAPTHPGD | |
| SCHEMBL24761596 | 0.87 | CYP1A2 (0.61) | HSD17B10KDM4EPOLBMAPTHPGD | |
| SCHEMBL28850353 | 0.87 | CYP1A2 (0.61) | HSD17B10KDM4EPOLBMAPTHPGD | |
| SCHEMBL11447283 | 0.86 | KDM4E (0.62) | HSD17B10KDM4EPOLBMAPTHPGD | |
| SCHEMBL11508863 | 0.86 | KDM4E (0.67) | HSD17B10KDM4EPOLBMAPTHPGD | |
| SCHEMBL11447282 | 0.86 | KDM4E (0.62) | HSD17B10KDM4EPOLBMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-12485181-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-12-02 | — | — | US | claimed |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-20250058053-A1 | OXYGEN SCAVENGER SYRINGE CAP | FRESENIUS KABI USA, LLC | 2025-02-20 | — | — | US | claimed |
| WO-2024226608-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | AGLAEAPHARMA INC. (US) | 2024-10-31 | — | — | WO | claimed |
| EP-4452371-A1 | OXYGEN SCAVENGER SYRINGE CAP | Fresenius Kabi USA, LLC (US) | 2024-10-30 | — | — | EP | claimed |
| US-20240316208-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | SERINA THERAPEUTICS (AL), INC. (US) | 2024-09-26 | — | — | US | claimed |
| US-20240294986-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2024-09-05 | — | — | US | claimed |
| US-20240293560-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | SERINA THERAPEUTICS (AL), INC. (US) | 2024-09-05 | — | — | US | claimed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| EP-0617001-B1 | Phenoxyphenylacetic acid derivatives | MERCK & CO INC (US) | 2000-01-26 | — | — | EP | claimed |
| EP-0587814-A1 | SUBSTITUTED PYRIMIDINONES BEARING ACIDIC FUNCTIONAL GROUPS AS ANGIOTENSIN II ANTAGONISTS | MERCK & CO. INC. (US) | 1994-03-23 | — | — | EP | claimed |
| WO-1992020687-A1 | SUBSTITUTED PYRIMIDINONES BEARING ACIDIC FUNCTIONAL GROUPS AS ANGIOTENSIN II ANTAGONISTS | MERCK & CO., INC. (US) | 1992-11-26 | — | — | WO | claimed |
| WO-1991015479-A1 | SUBSTITUTED PYRAZOLES, ISOXAZOLES AND ISOTHIAZOLES | MERCK & CO., INC. (US) | 1991-10-17 | — | — | WO | claimed |
| EP-0079522-B1 | N-CARBOXYMETHYL(AMIDINO)LYSYL-PROLINE ANTIHYPERTENSIVE AGENTS | MERCK & CO. INC. (US) | 1986-05-07 | — | — | EP | claimed |
| EP-0046291-B1 | SUBSTITUTED CAPROLACTAM DERIVATIVES AS ANTIHYPERTENSIVES, PROCESS FOR PREPARING THEM, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND INTERMEDIATES | MERCK & CO. INC. (US) | 1985-12-27 | — | — | EP | claimed |
| EP-0046289-B1 | SUBSTITUTED ENANTHOLACTAM DERIVATIVES AS ANTIHYPERTENSIVES, A PROCESS FOR PREPARING AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND INTERMEDIATES | MERCK & CO. INC. (US) | 1985-11-27 | — | — | EP | claimed |
| EP-0083923-A2 | Aminoacyl-containing dipeptide derivatives useful as antihypertensives | MERCK & CO. INC. (US) | 1983-07-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, SPOP, CYP2C19 | HSD17B10 2420/4885KDM4E 2755/4885POLB 1046/4885 |
| US-12485181-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, CYP2C19, CYP3A7 | HSD17B10 2609/4885KDM4E 2757/4885POLB 718/4885 |
| US-20240293560-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | CYP3A5, SPOP, CYP2C19 | HSD17B10 2420/4885KDM4E 2755/4885POLB 1046/4885 |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, SPOP, CYP2C19 | HSD17B10 2420/4885KDM4E 2755/4885POLB 1046/4885 |
| US-20240316208-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | CYP3A5, SPOP, CYP2C19 | HSD17B10 2420/4885KDM4E 2755/4885POLB 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.